Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma

QR Code

Efficacy and Safety of PD-1 Inhibitor Combined with Anlotinib on Advanced Neuroendocrine Carcinoma

Objective To analyze the efficacy and safety of PD-1 inhibitor combined with anlotinib on advanced neuroendocrine carcinoma. Methods We collected the data of patients with advanced neuroendocrine carcinoma who had failed the first-line standard chemotherapy and treated with PD-1 inhibitor combined w...

Full description

Saved in:

Bibliographic Details
Main Authors:	YU Xuxu, LI Xiangke, YANG Minjie, CHEN Zhong, MAO Yinggang, SONG Lijie
Format:	article
Language:	ZH
Published:	Magazine House of Cancer Research on Prevention and Treatment 2021
Subjects:	immune checkpoint inhibitor pd-1 anlotinib neuroendocrine carcinoma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Online Access:	https://doaj.org/article/186b970ee9bb445ab2de5a5302123faf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2021)

Progress of Immune Checkpoint Inhibitors  in the Treatment of Advanced Pulmonary Neuroendocrine Tumors
by: Haoqing CHEN, et al.
Published: (2021)

Malignant Melanoma With Neuroendocrine Differentiation: A Case Report and Literature Review
by: Jason Cham, et al.
Published: (2021)

Imaging of Neuroendocrine Prostatic Carcinoma
by: Ahmed Taher, et al.
Published: (2021)

Novel Nanocrystal Injection of Insoluble Drug Anlotinib and Its Antitumor Effects on Hepatocellular Carcinoma
by: Mei Luo, et al.
Published: (2021)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
by: Ewa Surmiak, et al.
Published: (2021)

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
by: Virginia Liberini, et al.
Published: (2021)

Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A
by: Gu G, et al.
Published: (2021)

Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts
by: Yoshihide Suzuki, et al.
Published: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
by: Kimberly M. Burcher, et al.
Published: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
by: Zou W, et al.
Published: (2021)

A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy
by: Yang H, et al.
Published: (2021)

Cardiac MRI in Immune Checkpoint Inhibitor Associated Pericarditis
by: Can Öztürk, et al.
Published: (2021)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
by: Mengqiu Tang, et al.
Published: (2021)

Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities
by: Haider Mahdi, et al.
Published: (2021)

Primary hepatic neuroendocrine carcinoma diagnosed by needle biopsy: a case report
by: Yusuke Seki, et al.
Published: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
by: Yixi Zhang, et al.
Published: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
by: LAI Yanliang, et al.
Published: (2021)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
by: Wolfram Samlowski, et al.
Published: (2021)

Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer
by: Liliang Xia, et al.
Published: (2021)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
by: Pei-Yi Chu, et al.
Published: (2021)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
by: Chang-Jin Jung, et al.
Published: (2021)

A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer
by: Yi-Dan Yan, et al.
Published: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
by: Zhitao Li, et al.
Published: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
by: Di Wang, et al.
Published: (2021)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
by: Jean-Marie Michot, et al.
Published: (2021)

Small cell neuroendocrine carcinoma expressing alpha fetoprotein in the endometrium
by: Hou Weiwei, et al.
Published: (2021)

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
by: Nicola Personeni, et al.
Published: (2021)

Effectiveness of anlotinib in patients with small‐cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study
by: Ying Liu, et al.
Published: (2021)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
by: Kennedy Yao Yi Ng, et al.
Published: (2021)

Successful Treatment of an Elderly Patient With Combined Small Cell Lung Cancer Receiving Anlotinib: A Case Report
by: Yuying Gan, et al.
Published: (2021)

Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature
by: Huanhuan Xu, et al.
Published: (2021)

Advances in Reproductive Endocrinology and Neuroendocrine Research Using Catfish Models
by: Balasubramanian Senthilkumaran, et al.
Published: (2021)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
by: Shubin Chen, et al.
Published: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
by: Peiyi Xie, et al.
Published: (2021)

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer
by: Yu Chen, et al.
Published: (2021)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
by: Sara Elena Rebuzzi, et al.
Published: (2021)

Biological Therapeutic Advances for the Treatment of Advanced Urothelial Cancers
by: Rizzo M, et al.
Published: (2021)

Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer
by: KE Ping, et al.
Published: (2021)